Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20733325 | 0.90 | CNR1 (0.44) | CNR1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL20733202 | 0.90 | POLB (0.49) | CNR1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL7547653 | 0.87 | REN (0.49) | KMT2APOLBALDH1A1MAPT | |
| SCHEMBL7576771 | 0.87 | POLB (0.49) | CNR1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL7559571 | 0.87 | KMT2A (0.45) | CNR1KMT2APOLBTDP1 | |
| SCHEMBL20302834 | 0.87 | MAPT (0.54) | KMT2APOLBMAPT | |
| SCHEMBL7567597 | 0.86 | REN (0.44) | CNR1KMT2APOLBTDP1 | |
| SCHEMBL7552996 | 0.85 | KMT2A (0.45) | KMT2ATDP1ALDH1A1MAPT | |
| SCHEMBL7538262 | 0.85 | RAB9A (0.45) | KMT2APOLBALDH1A1MAPT | |
| SCHEMBL7565742 | 0.85 | IDO1 (0.45) | CNR1KMT2APOLBTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046507-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | MERCK SHARP & DOHME CORP. (US) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046507-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | CTSL, SERPINB1, SERPINE1 | CNR1 3210/4885KMT2A 3046/4885POLB 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.